Clinical

Bipolar disorder (BPD) is a chronic, recurrent psychiatric illness characterized by episodes of bothmania and depression. It is estimated that up to 2.6% of the US adult population is affected by this disorder,1 and that the lifetime prevalence rate for bipolar spectrum disorders ranges from 3.0% to 6.5%.2 Direct treatment costs are sizable, at $11,600 per patient-year.3 Medication is an essential part of successful treatment for BPD.

Health Plans’ Approaches to Managing Appropriate Use of Antipsychotic Drugs

Robert Henry: Two recent articles on ProvenCare discussed Geisinger’s innovative approach to patient care.1,2 Could you provide a quick synopsis of ProvenCare, and consider whether this system could help transform US healthcare from a sickness-based to a wellness-based system?

Diabetes mellitus affects 23.6 million Americans, or about 8% of the US population.1 This includes nearly 18 million persons with diagnosed disease and about 5.7 million undiagnosed cases.

Diabetes: An Epidemic of Disastrous Proportions

The prevalence of hypothyroidism in the United States is estimated at 4% to 10%, including undiagnosed cases.1,2 Higher rates have been found in women and the elderly.1,2 The most common causes of hypothyroidism are autoimmune thyroid disease and surgical or radioiodine ablation; only a small percentage of cases result from secondary causes.3,4

Health Insurance Premium Increases for Large Employers

Hypertension affects approximately 1 of 3 adults in the United States, and about 2 million new cases are diagnosed each year.1,2 An additional 28% of the US population is afflicted with prehypertension, and approximately 7% of Americans are not aware that they even have hypertension.3 Globally, hypertension affects more than 1 billion people and is projected to reach 1.56 billion by 2025.4 It is the leading cause of death and the second leading cause of lost disability-adjusted life-years worldwide.4 Randomized controlled clinical trials have show

Hypertension Management: Implications to Patients, Providers, and Payers

Allergic rhinitis (AR) has a significant detrimental effect on a patient's quality of life (QoL), affecting sleep, normal daily activities, and work.1-4 Stempel and Woolf estimated that the 50 million Americans with AR spend more than $6 billion annually on prescription and nonprescription medications to relieve AR symptoms.5,6 Despite a growing body of literature on the effect of AR on QoL, there is a paucity of studies that use QoL findings to assess the cost-effectiveness of various agents used to treat AR.

Allergic Rhinitis: A Serious Condition with Many Safe and Effective Pharmaceutical Options

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States.

The 10,000-Life Measure Shows Real-World Costs of Disease Burden and Interventions on a Population

Bipolar disorder (BPD) is characterized by cyclic mood swings of manic, hypomanic, and depressive episodes. BPD often begins in adolescence or early adulthood and continues throughout life, with recurring mood episodes. Estimated relapse rates during the first year after illness onset range between 37% and 44%.1,2 Globally, BPD is a major cause of disability, suicide, and death.3

Bipolar Disorder Prevalence Often Underestimated
Page 12 of 12
Results 111 - 118 of 118
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME